Alnylam Pharmaceuticals (ALNY) Receivables - Net (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Receivables - Net for 18 consecutive years, with $912.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net rose 60.95% year-over-year to $912.7 million; the trailing twelve-month figure through Jun 2026 stood at $912.7 million (up 60.95% YoY), and the FY2025 full-year result was $777.6 million, up 91.85% from the prior year.
• Receivables - Net grew to $912.7 million in Q2 2026 per ALNY's latest filing, from $884.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $964.8 million in Q3 2025 and bottomed at $142.3 million in Q2 2022.
• Historically, Receivables - Net has averaged $429.4 million across 5 years, with a median of $326.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Receivables - Net dropped 2.94% in 2022, then jumped 172.65% in 2025.
• Over 5 years, Receivables - Net stood at $238.0 million in 2022, then jumped by 37.75% to $327.8 million in 2023, then rose by 23.65% to $405.3 million in 2024, then surged by 91.85% to $777.6 million in 2025, then advanced by 17.38% to $912.7 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $912.7 million, $884.0 million, and $777.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.